

# A Multicenter, Randomized, Crossover Clinical Trial Study of Digital Intelligence Software in Patients With MAFLD

NCT07233486

---

Status	RECRUITING
Phase	Not Applicable
Sponsor	The Affiliated Hospital of Hangzhou Normal University
Enrollment	2,000 participants

## Key Eligibility Criteria

---

### Inclusion (5)

- Adult patients aged 18-65 years with a BMI of 24-35 kg/m<sup>2</sup>.
- Confirmed diagnosis of Metabolic-associated Fatty Liver Disease (MAFLD), defined by a FibroScan® result  $\geq 248$  dB/m or an MRI-PDFF  $\geq 5\%$ .
- Willing and able to provide written informed consent and comply with the study protocol, including the use of a compatible smartphone for digital health components.
- If treated for Type 2 Diabetes Mellitus (T2DM), must be on a stable medication regimen for at least 3 months prior to baseline (Day 0), with the expectation to maintain stability throughout the study barring medical necessity.
- If taking medications with potential NASH-remitting effects (e.g., vitamin E, thiazolidinediones), must be on a stable dose for at least 3 months prior to Day 0.

### Exclusion (34)

- Subjects were excluded from participation if they met any of the following criteria, based on the most recent pre-randomization assessments:
- Evidence of cirrhosis, defined as histological stage F4 or its clinical equivalent.
- History of heavy alcohol consumption ( $\geq 30$  g/day for males,  $\geq 20$  g/day for females) for more than 3 consecutive months within one year prior to screening.
- Prior or planned solid organ transplantation (excluding corneal transplants).
- Planned bariatric surgery. A history of bariatric surgery was permitted only if weight had been stable (variation  $<10\%$ ) for at least 3 months prior to screening.

... and 29 more (see full listing online)

## Locations (1 total)

---

Hangzhou Normal University Hospital, Hangzhou, Zhejiang, China